BioNexus Gene Lab Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 19, 2026, disclosing condensed consolidated financial statements and related notes.
Key Highlights
- Total assets of $8,760,701 as of September 30, 2026, compared with $9,252,784 as of December 31, 2025, according to the filing.
- Accumulated deficit of $8,311,633 as of September 30, 2026, up from $6,427,227 as of December 31, 2025, the company disclosed.
- Cash and bank balances of $865,804 as of September 30, 2026, down from $2,383,369 as of December 31, 2025, per the filing.
- Trade receivables of $38,142 (net of allowance for credit losses of $773,304) as of September 30, 2026, compared with $505,885 as of December 31, 2025.
- Shares outstanding of 2,933,442 as of September 30, 2026, rising to 3,493,442 as of November 19, 2026, the filing stated.
- Total stockholders' equity of $7,521,208 as of September 30, 2026, compared with $8,614,928 as of December 31, 2025.
BioNexus Gene Lab Balance Sheet Highlights for the Quarter Ended September 30, 2026
According to the Form 10-Q filed on November 19, 2026 with the SEC, BioNexus Gene Lab Corp. (NASDAQ:BGLC), a Wyoming-incorporated company headquartered in Kuala Lumpur, Malaysia, reported total assets of $8,760,701 as of September 30, 2026. This compares to total assets of $9,252,784 as of December 31, 2025. Current assets declined to $4,188,577 from $5,365,405 over the same period, driven in part by a decrease in cash and bank balances from $2,383,369 to $865,804.
The filing disclosed that trade receivables, net of an allowance for credit losses of $773,304, stood at $38,142 as of September 30, 2026, a sharp reduction from $505,885 net of a $703,995 allowance at year-end 2025. The company also reported inventories of $636,226 and fixed deposits of $2,497,798, which included $1,139,737 of deposits with original maturities of more than three months. Non-current assets increased to $4,572,124 from $3,887,379, reflecting a rise in other assets from $83,333 to $833,330 and the addition of finance lease right-of-use assets of $69,424.
Total liabilities grew to $1,239,493 from $637,856 at December 31, 2025. The filing noted that amounts owing to directors increased to $230,277 from $49,479, and other payables to related parties rose to $504,330 from $83,333. The accumulated deficit widened to $8,311,633 from $6,427,227 over the nine-month period. The company disclosed that common stock shares outstanding were 2,933,442 as of September 30, 2026, and had increased to 3,493,442 by November 19, 2026. The filing noted that shares for periods prior to April 7, 2025 have been adjusted to reflect a 1-for-10 reverse stock split effected on that date, and for periods prior to July 20, 2023 to reflect a 1-for-12 reverse stock split, both on a retroactive basis. The filing contains forward-looking statements that, the company stated, are subject to risks and uncertainties described in its Annual Report on Form 10-K and elsewhere in the quarterly report.
What Was Disclosed
BioNexus Gene Lab Corp. filed a Form 10-Q for the quarter ended September 30, 2026, reporting total assets of $8,760,701, an accumulated deficit of $8,311,633, total liabilities of $1,239,493, and 3,493,442 shares outstanding as of November 19, 2026.




Please wait processing your request...